Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241873 · ClinicalTrials.gov registry record · Phase 1
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT05241873 is a Phase 1 study that was terminated before completion, run by Blueprint Medicines Corporation. The registered enrollment target is 103 participants.
The verdict
NCT05241873, a Phase 1 study, was terminated before completion, sponsored by Blueprint Medicines Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG BLU-451
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05241873
The ClinicalTrials.gov registry entry for NCT05241873 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT05241873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05241873 about?
NCT05241873 is a clinical study titled "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations". This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day trea...
What is the current status of trial NCT05241873?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2022-03-04. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05241873?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), BLU-451 (DRUG).
Who is sponsoring clinical trial NCT05241873?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.